Clinical trial
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif®…
NCT00050778 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00050778 |
|---|---|
| Title | A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis |
| Official title | A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Biological |
| Interventions | Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg |
| Enrollment | 334 |
| Start date | Dec 1, 2002 |
| Primary completion | Sep 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Dec 23, 2002 |
| Last update posted | Jan 8, 2015 |
| Countries | Croatia, Poland, Russia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: